IPHA - Innate Pharma S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.45
-0.25 (-3.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.70
Open6.25
Bid6.00 x 1100
Ask6.45 x 800
Day's Range6.00 - 6.45
52 Week Range3.30 - 8.24
Volume2,984
Avg. Volume17,730
Market Cap490.41M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
42% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Innate Pharma S.A. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
      Simply Wall St.

      Innate Pharma S.A. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

      Shareholders in Innate Pharma S.A. (EPA:IPH) had a terrible week, as shares crashed 30% to €4.56 in the week since its...

    • GlobeNewswire

      First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Phase I clinical trial evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in adult patients with advanced solid tumors. The purpose of the study, which is sponsored by AstraZeneca (LSE/STO/NYSE: AZN), is to evaluate IPH5201 as monotherapy and in combination with durvalumab (anti-PD-L1) with or without oleclumab (anti-CD73 monoclonal antibody).

    • GlobeNewswire

      First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Phase I clinical trial evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in adult patients with advanced solid tumors. The purpose of the study, which is sponsored by AstraZeneca (LSE/STO/NYSE: AZN), is to evaluate IPH5201 as monotherapy and in combination with durvalumab (anti-PD-L1) with or without oleclumab (anti-CD73 monoclonal antibody).

    • GlobeNewswire

      Innate Pharma Reports Full Year 2019 Financial Results and Business Update

      Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million1)Monalizumab.

    • GlobeNewswire

      SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA

      Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

    • GlobeNewswire

      IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – IPHA

      NEW YORK, Feb. 10, 2020 -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Innate.

    • ACCESSWIRE

      SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm

      LOS ANGELES, CA / ACCESSWIRE / February 3, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or "the Company") (NASDAQ:IPHA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The Company's decision was based on "ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company's manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials." Based on this news, shares of Innate fell by nearly 10% on the same day.

    • GlobeNewswire

      SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHA

      Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

    • Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?
      Simply Wall St.

      Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?

      While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

    • GlobeNewswire

      French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy. Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.

    • GlobeNewswire

      French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy. Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.

    • ACCESSWIRE

      Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innate Pharma S.A. (IPHA)

      NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Innate Pharma S.A. ("Innate" or the Company") ...

    • GlobeNewswire

      SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHA

      Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

    • GlobeNewswire

      INNATE PHARMA PROVIDES UPDATE FROM REGULATORY AGENCIES ON LACUTAMAB TELLOMAK TRIAL

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. The Company has been in ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials. Based on these discussions, on December 13, 2019, the Company decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.

    • Benzinga

      The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

      The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) Aptose Biosciences Inc (NASDAQ: APTO ) ...

    • GlobeNewswire

      The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti® (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

    • GlobeNewswire

      The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti® (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. “If approved by the EMA, Lumoxiti will be the first treatment available in Europe for relapsed or refractory hairy cell leukemia patients in more than twenty years, potentially changing the standard of care for these patients,” commented Pierre Dodion, MD, Executive Vice President and Chief Medical Officer of Innate Pharma.

    • GlobeNewswire

      Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

      Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102, a potentially first-in-class anti-KIR3DL2 antibody). Lacutamab will not be administered to new patients in the TELLOMAK trial until additional feedback is received from the respective regulatory agencies overseeing our clinical trial.